Heather Anne Parsons, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 25 | 2024 | 21206 | 1.390 |
Why?
|
DNA, Neoplasm | 5 | 2017 | 1744 | 0.980 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2024 | 934 | 0.850 |
Why?
|
Neoplasm, Residual | 4 | 2024 | 1015 | 0.800 |
Why?
|
Estrogen Receptor alpha | 2 | 2020 | 581 | 0.600 |
Why?
|
Receptor, erbB-2 | 8 | 2024 | 2603 | 0.580 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9419 | 0.580 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 952 | 0.470 |
Why?
|
Anticarcinogenic Agents | 1 | 2015 | 251 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 11878 | 0.420 |
Why?
|
Camptothecin | 2 | 2024 | 600 | 0.360 |
Why?
|
Tamoxifen | 1 | 2015 | 966 | 0.350 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4055 | 0.330 |
Why?
|
Neoplasm Metastasis | 6 | 2021 | 4912 | 0.270 |
Why?
|
Immunoconjugates | 2 | 2024 | 975 | 0.270 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2024 | 3671 | 0.260 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3603 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.230 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2907 | 0.220 |
Why?
|
Quinolines | 3 | 2024 | 772 | 0.200 |
Why?
|
Mutation | 13 | 2024 | 30238 | 0.190 |
Why?
|
Maintenance | 1 | 2021 | 25 | 0.190 |
Why?
|
Early Detection of Cancer | 1 | 2016 | 3239 | 0.190 |
Why?
|
Female | 32 | 2024 | 397192 | 0.180 |
Why?
|
Semen | 1 | 2023 | 349 | 0.170 |
Why?
|
Burning Mouth Syndrome | 1 | 2000 | 25 | 0.170 |
Why?
|
Receptors, Progesterone | 1 | 2024 | 1160 | 0.170 |
Why?
|
Prospective Studies | 7 | 2024 | 54926 | 0.160 |
Why?
|
Receptors, Estrogen | 2 | 2024 | 2253 | 0.160 |
Why?
|
Humans | 45 | 2024 | 768166 | 0.160 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13676 | 0.150 |
Why?
|
Perception | 1 | 2024 | 1209 | 0.150 |
Why?
|
Neoplasms | 7 | 2023 | 22371 | 0.150 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2019 | 150 | 0.140 |
Why?
|
Centrosome | 2 | 2015 | 210 | 0.140 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 6082 | 0.140 |
Why?
|
Prognosis | 4 | 2024 | 30010 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2022 | 3556 | 0.130 |
Why?
|
Adult | 14 | 2024 | 223646 | 0.120 |
Why?
|
Aged | 12 | 2024 | 171504 | 0.120 |
Why?
|
Phlebotomy | 1 | 2015 | 138 | 0.120 |
Why?
|
DNA Mutational Analysis | 3 | 2017 | 4120 | 0.120 |
Why?
|
Middle Aged | 15 | 2024 | 223492 | 0.110 |
Why?
|
Drug Therapy | 1 | 2016 | 504 | 0.110 |
Why?
|
DNA Copy Number Variations | 2 | 2021 | 2048 | 0.100 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2021 | 1107 | 0.100 |
Why?
|
Loss of Heterozygosity | 1 | 2014 | 663 | 0.100 |
Why?
|
Nurses | 1 | 2021 | 2501 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 8647 | 0.090 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9118 | 0.090 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6847 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1829 | 0.080 |
Why?
|
DNA Methylation | 1 | 2024 | 4428 | 0.080 |
Why?
|
Mutation, Missense | 2 | 2015 | 2592 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1767 | 0.080 |
Why?
|
BRCA2 Protein | 1 | 2014 | 802 | 0.080 |
Why?
|
DNA | 3 | 2023 | 7214 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2015 | 1155 | 0.080 |
Why?
|
Survival Rate | 2 | 2020 | 12840 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2346 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8542 | 0.070 |
Why?
|
Sequence Analysis, DNA | 3 | 2024 | 4786 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1099 | 0.070 |
Why?
|
Prevalence | 1 | 2024 | 15869 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2565 | 0.070 |
Why?
|
Models, Genetic | 1 | 2015 | 3447 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2892 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2954 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6793 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Sulfites | 1 | 2024 | 83 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2015 | 3445 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5210 | 0.050 |
Why?
|
Antigens, Neoplasm | 2 | 2024 | 1997 | 0.050 |
Why?
|
Telomere-Binding Proteins | 1 | 2004 | 122 | 0.050 |
Why?
|
Phthalazines | 1 | 2024 | 397 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 81762 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11244 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2024 | 59629 | 0.050 |
Why?
|
Hyperesthesia | 1 | 2000 | 23 | 0.040 |
Why?
|
Platinum | 1 | 2021 | 222 | 0.040 |
Why?
|
Quality of Life | 1 | 2022 | 13490 | 0.040 |
Why?
|
GABA Modulators | 1 | 2000 | 109 | 0.040 |
Why?
|
Xerostomia | 1 | 2000 | 94 | 0.040 |
Why?
|
Tongue Diseases | 1 | 2000 | 69 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 631 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4362 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 797 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15454 | 0.040 |
Why?
|
Nucleosomes | 1 | 2022 | 492 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 667 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 17140 | 0.040 |
Why?
|
Heterozygote | 2 | 2015 | 2798 | 0.040 |
Why?
|
Breast | 2 | 2019 | 1976 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39348 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1613 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 960 | 0.040 |
Why?
|
Alleles | 2 | 2022 | 6894 | 0.040 |
Why?
|
Nucleic Acid Denaturation | 1 | 2017 | 111 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2022 | 2227 | 0.030 |
Why?
|
Pain Threshold | 1 | 2000 | 607 | 0.030 |
Why?
|
Microchemistry | 1 | 2015 | 55 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2015 | 10474 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 863 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2015 | 351 | 0.030 |
Why?
|
Heredity | 1 | 2015 | 149 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1733 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 13045 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2015 | 866 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2059 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3800 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 435 | 0.030 |
Why?
|
Age Factors | 2 | 2021 | 18412 | 0.030 |
Why?
|
Hemolysis | 1 | 2015 | 417 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2015 | 476 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1219 | 0.030 |
Why?
|
Hemoglobins | 1 | 2018 | 1531 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 1647 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 427 | 0.020 |
Why?
|
Signal Transduction | 1 | 2015 | 23645 | 0.020 |
Why?
|
Gene Targeting | 1 | 2015 | 841 | 0.020 |
Why?
|
Plasma | 1 | 2015 | 585 | 0.020 |
Why?
|
Tubulin | 1 | 2015 | 695 | 0.020 |
Why?
|
Aneuploidy | 1 | 2015 | 573 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1778 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 716 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 905 | 0.020 |
Why?
|
Homozygote | 1 | 2015 | 1779 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1536 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2521 | 0.020 |
Why?
|
Quinazolines | 1 | 2015 | 1373 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3568 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8741 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2463 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8509 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3968 | 0.020 |
Why?
|
Gene Frequency | 1 | 2015 | 3623 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2015 | 1489 | 0.020 |
Why?
|
Thiazoles | 1 | 2015 | 1542 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5027 | 0.020 |
Why?
|
Animals | 3 | 2016 | 169246 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5755 | 0.020 |
Why?
|
Phenotype | 2 | 2015 | 16726 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2932 | 0.020 |
Why?
|
Genome | 1 | 2015 | 1754 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10399 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2832 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15597 | 0.020 |
Why?
|
Models, Statistical | 1 | 2021 | 5107 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2015 | 4283 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10101 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2885 | 0.020 |
Why?
|
Male | 5 | 2023 | 364719 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12077 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5902 | 0.020 |
Why?
|
Primary Health Care | 1 | 2021 | 4746 | 0.010 |
Why?
|
Homeostasis | 1 | 2015 | 3348 | 0.010 |
Why?
|
Baculoviridae | 1 | 2004 | 115 | 0.010 |
Why?
|
Software | 1 | 2017 | 4478 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7454 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7477 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26422 | 0.010 |
Why?
|
Glutathione Transferase | 1 | 2004 | 564 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 74944 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2004 | 563 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2004 | 1989 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2015 | 14488 | 0.010 |
Why?
|
Protein Folding | 1 | 2004 | 871 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3772 | 0.010 |
Why?
|
Kinetics | 1 | 2004 | 6329 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41754 | 0.010 |
Why?
|
Binding Sites | 1 | 2004 | 6020 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11101 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 24315 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40218 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 18065 | 0.010 |
Why?
|
United States | 1 | 2020 | 73039 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9343 | 0.010 |
Why?
|
Escherichia coli | 1 | 2004 | 4214 | 0.010 |
Why?
|
Mice | 1 | 2015 | 82029 | 0.000 |
Why?
|